person · Reporting owner
Stacey Jennifer Evans
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Context Therapeutics Inc.CNTX · Entity 7406 | Director | June 24, 2026 | June 26, 2026 |
| Galera Therapeutics, Inc.GRTX · Entity 15899 | See Remarks | February 25, 2023 | February 28, 2023 |
| NEOGEN CORPNEOG · Entity 4338 | Chief Legal Officer | August 14, 2026 | August 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Context Therapeutics Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2036-06-23 | Direct | 45,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 45,000 · Balance 45,000 F1: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.
Galera Therapeutics, Inc.
Report date February 25, 2023 · Filed February 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.78 · Expires 2033-02-24 | Direct | 135,000 |
Reported balance
After 2023-02-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-25 · Grant · Acquired 135,000 · Balance 135,000 F1: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 25, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 25, 2023.
NEOGEN CORP
Report date August 14, 2026 · Filed August 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,627 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 38,627 · Balance 38,627 F2: PSUs vest in total at the end of the three year anniversary date of the grant |
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.65 · Expires 2036-08-14 | Direct | 196,276 |
Reported balance
After 2026-08-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-14 · Grant · Acquired 196,276 · Balance 196,276 F1: Options vest in equal annual installments on each of the first three anniversary dates of the grants |
Filing footnotes · ownership attribution and instrument terms
F1: Options vest in equal annual installments on each of the first three anniversary dates of the grants
F2: PSUs vest in total at the end of the three year anniversary date of the grant
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 15, 2026 00:58 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock (Right to Buy) · Derivative | 196,276 | $0.00 Strike: $11.65 | $0.00 |
DisclosureSEC source: 0000711377-26-000016 · primary_doc.xml · derivative · entry 2 Stacey Jennifer Evans · CIK 0001321326 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,276 Underlying: Common Stock · 196,276 shares Expires 2036-08-14 F1 · derivative.exercise_date: Options vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| August 14, 2026 Filed Aug 15, 2026 00:58 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock | 38,627 | $11.65 | $450,004.55 |
DisclosureSEC source: 0000711377-26-000016 · primary_doc.xml · nonDerivative · entry 1 Stacey Jennifer Evans · CIK 0001321326 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,627 F2 · shares: PSUs vest in total at the end of the three year anniversary date of the grant Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 20:21 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001628280-26-045784 · wk-form4_1782505299.xml · derivative · entry 1 Stacey Jennifer Evans · CIK 0001321326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:52 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock (Right to Buy) · Derivative | 89,520 | $0.00 Strike: $9.53 | $0.00 |
DisclosureSEC source: 0000711377-26-000008 · primary_doc.xml · derivative · entry 2 Stacey Jennifer Evans · CIK 0001321326 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,520 Underlying: Common Stock · 89,520 shares Expires 2036-05-01 F1 · derivative.exercise_date: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:52 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock | 39,349 | $9.53 | $374,995.97 |
DisclosureSEC source: 0000711377-26-000008 · primary_doc.xml · nonDerivative · entry 1 Stacey Jennifer Evans · CIK 0001321326 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,349 F1 · shares: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| June 12, 2025 Filed Jun 12, 2025 21:25 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 123,500 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001842952-25-000075 · wk-form4_1749763548.xml · derivative · entry 1 Stacey Jennifer Evans · CIK 0001321326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,500 Underlying: Common Stock · 123,500 shares Expires 2035-06-11 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 12, 2026 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2026 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 11:52 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001842952-24-000048 · wk-form4_1718365971.xml · derivative · entry 1 Stacey Jennifer Evans · CIK 0001321326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2025 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| May 31, 2023 Filed May 31, 2023 20:53 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001842952-23-000060 · wf-form4_168556637918497.xml · derivative · entry 1 Stacey Jennifer Evans · CIK 0001321326 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) May 31, 2024 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2024 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| February 25, 2023 Filed Feb 28, 2023 23:56 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0000899243-23-006467 · doc4.xml · derivative · entry 1 Stacey Jennifer Evans · CIK 0001321326 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2033-02-24 F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 25, 2023. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:09 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001842952-22-000057 · wf-form4_165428693172276.xml · derivative · entry 1 Stacey Jennifer Evans · CIK 0001321326 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: 1.The option vests and becomes exercisable on the earlier of (i) June 2, 2023 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2023 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:06 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0000899243-22-008582 · doc4.xml · derivative · entry 1 Stacey Jennifer Evans · CIK 0001321326 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-27 F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 28, 2022. Read SEC document |
| October 08, 2021 Filed Oct 13, 2021 00:20 UTC | Galera Therapeutics, Inc. GRTX · Entity 15899 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0000899243-21-039956 · doc4.xml · derivative · entry 1 Stacey Jennifer Evans · CIK 0001321326 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2031-10-07 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% on October 8, 2022, and in thirty-six (36) substantially equal monthly installments over a three year period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.